Failure of liposomally encapsulated adriamycin to improve therapeutic efficacy for cancer cells in vitro.

The anticancer drug Adriamycin was tested in vitro both in free form and encapsulated in negatively charged liposomes. [3H]-thymidine incorporation and a 72-hour survival test were used for the evaluation of cytotoxicity in a phagocytic human melanoma cell line and a non-phagocytic human ovarian carcinoma cell line. In each case, free Adriamycin induced… (More)